News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Protox Therapeutics Inc. (PRX.V) Appoints Richard Yocum as Chief Medical Officer



12/12/2011 9:03:01 AM

SAN DIEGO, CA and VANCOUVER, Dec. 12, 2011 - Protox Therapeutics Inc. ("Protox", TSX: PRX), a developer of innovative products for the treatment of urological diseases, today announced the appointment of Dr. Richard Yocum as Chief Medical Officer, located in San Diego.

Dr. Yocum joined Protox in November 2011 and brings 29 years of medical and drug development experience to the company. Before Protox he served as Vice President of Drug/Clinical Development and Medical Affairs at Rockwell Medical Technologies, Halozyme Pharmaceuticals, and Chugai Pharma USA. This was preceded by clinical research experience as Executive Medical Director at Ligand Pharmaceuticals and Associate Director at Gensia. Dr. Yocum has a proven track record of success with multiple product approvals across several therapeutic areas, in the US, Canada, and Europe. He brings direct hands-on experience leading efficient, streamlined, high quality clinical teams across all phases of clinical development including the preparation and submission of eight regulatory dossiers for drug approval.

Dr. Lars Ekman, Executive Chairman and President said, "Dr. Yocum's clinical development ?expertise and impressive track record will be key to the success of? Protox."

Dr. Yocum graduated summa cum laude from Dartmouth College and earned his medical degree from the Johns Hopkins University School of Medicine. Dr. Yocum is board certified in Internal Medicine, completing his residency at the University of California San Diego, and has maintained an Internal Medicine practice for 10 years.

About Protox

Protox Therapeutics is a developer of innovative products for the treatment of urological diseases. Protox's lead program, PRX302 (PORxin), achieved positive results from its Phase 2b placebo controlled trial called TRIUMPH, to treat benign prostatic hyperplasia (BPH or enlarged prostate). Protox has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. For more information, please visit www.protoxtherapuetics.com. Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Protox' current beliefs as well as assumptions made by and information currently available to Protox and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Protox in its public securities filings; actual events may differ materially from current expectations. Protox disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES